Dias, B.B.; Carreño, F.; Helfer, V.E.; Garzella, P.M.B.; de Lima, D.M.F.; Barreto, F.; de Araújo, B.V.; Dalla Costa, T.
Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling. Pharmaceutics 2022, 14, 1237.
https://doi.org/10.3390/pharmaceutics14061237
AMA Style
Dias BB, Carreño F, Helfer VE, Garzella PMB, de Lima DMF, Barreto F, de Araújo BV, Dalla Costa T.
Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling. Pharmaceutics. 2022; 14(6):1237.
https://doi.org/10.3390/pharmaceutics14061237
Chicago/Turabian Style
Dias, Bruna Bernar, Fernando Carreño, Victória Etges Helfer, Priscila Martini Bernardi Garzella, Daiane Maria Fonseca de Lima, Fabiano Barreto, Bibiana Verlindo de Araújo, and Teresa Dalla Costa.
2022. "Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling" Pharmaceutics 14, no. 6: 1237.
https://doi.org/10.3390/pharmaceutics14061237
APA Style
Dias, B. B., Carreño, F., Helfer, V. E., Garzella, P. M. B., de Lima, D. M. F., Barreto, F., de Araújo, B. V., & Dalla Costa, T.
(2022). Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling. Pharmaceutics, 14(6), 1237.
https://doi.org/10.3390/pharmaceutics14061237
